Tailoring T Profiles Enhances Antibody Persistence to a Clade C HIV-1 Vaccine in Rhesus Macaques
Authors
Affiliations
CD4 T follicular helper cells (T) are essential for establishing serological memory and have distinct helper attributes that impact both the quantity and quality of the antibody response. Insights into T subsets that promote antibody persistence and functional capacity can critically inform vaccine design. Based on the T profiles evoked by the live attenuated measles virus vaccine, renowned for its ability to establish durable humoral immunity, we investigated the potential of a T1/17 recall response during the boost phase to enhance persistence of HIV-1 Envelope (Env) antibodies in rhesus macaques. Using a DNA-prime encoding gp160 antigen and T polarizing cytokines (interferon protein-10 (IP-10) and interleukin-6 (IL-6)), followed by a gp140 protein boost formulated in a cationic liposome-based adjuvant (CAF01), we successfully generated germinal center (GC) T1/17 cells. In contrast, a similar DNA-prime (including IP-10) followed by gp140 formulated with monophosphoryl lipid A (MPLA) +QS-21 adjuvant predominantly induced GC T1 cells. While the generation of GC T1/17 cells with CAF01 and GC T1 cells with MPLA +QS-21 induced comparable peak Env antibodies, the latter group demonstrated significantly greater antibody concentrations at week 8 after final immunization which persisted up to 30 weeks (gp140 IgG ng/ml- MPLA; 5500; CAF01, 2155; p<0.05). Notably, interferon +Env-specific T responses were consistently higher with gp140 in MPLA +QS-21 and positively correlated with Env antibody persistence. These findings suggest that vaccine platforms maximizing GC T1 induction promote persistent Env antibodies, important for protective immunity against HIV.
Pekarek M, Madapong A, Wiggins J, Weaver E Int J Mol Sci. 2025; 26(4).
PMID: 40004004 PMC: 11855595. DOI: 10.3390/ijms26041538.
Recent Advances in the Development of Mincle-Targeting Vaccine Adjuvants.
Weth A, Dangerfield E, Timmer M, Stocker B Vaccines (Basel). 2025; 12(12.
PMID: 39771982 PMC: 11680293. DOI: 10.3390/vaccines12121320.
Perdiguero B, Hauser A, Gomez C, Peterhoff D, Sideris E, Sorzano C Front Immunol. 2023; 14:1270908.
PMID: 38045703 PMC: 10690772. DOI: 10.3389/fimmu.2023.1270908.